Clinical Trials Logo

Filter by:
NCT ID: NCT02722551 Withdrawn - Clinical trials for Mitral Valve Regurgitation

CardiAQ-Edwards™ Transcatheter Mitral Valve Replacement (TMVR) Study

RELIEF
Start date: November 2016
Phase: Phase 1/Phase 2
Study type: Interventional

Clinical study to evaluate the safety and performance of the CardiAQ-Edwards™ Transcatheter Mitral Valve

NCT ID: NCT02713880 Withdrawn - Clinical trials for Transthyretin Amyloidosis

Biomarker for Transthyretin-Related Familial Amyloidotic Polyneuropathy (BioTRAP)

BioTRAP
Start date: August 20, 2018
Phase:
Study type: Observational

International, multicenter, observational, longitudinal study to identify biomarker/s for the development of a new MS-based biomarker for the early and sensitive diagnosis of Transthyretin-Related Familial Amyloidotic Polyneuropathy from blood and number of correctly identified patients with Transthyretin-Related Familial Amyloidotic Polyneuropathy

NCT ID: NCT02682615 Withdrawn - Cardiac Output Clinical Trials

Non-invasive Cardiac Output Monitoring (esCCO™) in Critically Ill Patients Within ICU

Start date: August 1, 2017
Phase:
Study type: Observational

Evaluation of a non-invasive technique to measure cardiac output (esCCO™) with the "clinical goldstandard" of the transcardiopulmonal thermodilution technique (PiCCO®). Effect of different potential interference factors to the accuracy of measurement (changing concentration of norepinephrine, generally severity of the basic disease - APACHE II score).

NCT ID: NCT02658526 Withdrawn - Behavioral Clinical Trials

Cognitive Changes in Childs After Anesthesia / Surgery

Start date: December 2015
Phase:
Study type: Observational

The role of surgical stress and anesthesia is unknown in the early childhood. In vitro and animal studies showed a risk for treatment with anesthesia in the developmental brain. Furthermore, stress is also an important risk factor for cognitive impairment. Therefore, the investigators want to investigate in a clinical prospective cohort study the role anesthesia and surgery on different cognitive parameters and self-controling mechanisms in children under 3 years.

NCT ID: NCT02657447 Withdrawn - Clinical trials for Non-Hodgkin Lymphoma

Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)

Start date: December 19, 2017
Phase: Phase 1
Study type: Interventional

This study is a phase I, open label, randomized study to assess pharmacokinetics, biodistribution and radiation dosimetry of lutetium (177Lu) lilotomab satetraxetan (Betalutin®) radioimmunotherapy in patients with relapsed non-Hodgkin lymphoma. The study will also investigate the safety, toxicity and efficacy of Betalutin and pre-dosing.

NCT ID: NCT02645201 Withdrawn - Clinical trials for Helicobacter Infections

The Effect of Probiotic Combination on Helicobacter Pylori Infection in Children

Gastrus
Start date: January 2016
Phase: N/A
Study type: Interventional

The combination of two Lactubacillus reuteri strains, ATC 55730 and ATCC PTA 6457 are marketed as GASTRUS® and has been proposed as better option in increasing Helicobacter pylori eradication rate compared to the single strain ATC 55730, due to additional anti-inflammatory properties of the second strain. Objectives of the study are to determine whether adding probiotic combination (GASTRUS®) to an anti- Helicobacter pylori regimen decreases adverse events and increases the eradication rate of Helicobacter pylori in the pediatric population infected with Helicobacter pylori bacteria.

NCT ID: NCT02605356 Withdrawn - Multiple Myeloma Clinical Trials

Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma

Start date: October 2016
Phase: Phase 1/Phase 2
Study type: Interventional

This study will be conducted in 2 parts. The phase 1b part will be an international, phase 1b, open-label, dose-escalation assessment of radium-223 dichloride administered with bortezomib and dexamethasone in subjects with relapsed multiple myeloma. The primary endpoint of the phase 1b part is to determine the optimal dose of radium-223 dichloride in combination with bortezomib/dexamethasone for the Phase 2 portion of the study. The phase 2 part will be an international, phase 2, double-blind, randomized, placebo-controlled assessment of radium-223 dichloride versus placebo administered with bortezomib and dexamethasone, in subjects with relapsed multiple myeloma. Randomization (1:1) in the phase 2 part will be stratified by: - Prior bortezomib treatment (yes, no) - Prior treatment (1 prior line of treatment, >1 prior line of treatment) Approximately 30 subjects (10 subjects per cohort) will be enrolled in the phase 1b part of the study and approximately 196 subjects will be enrolled in the phase 2 part of the study.

NCT ID: NCT02603042 Withdrawn - Clinical trials for Defective Mineralization

Biomarker for Hypophosphatasia Disease (BioHypophos)

BioHypophos
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new MS-based biomarker for the early and sensitive diagnosis of Hypophosphatasia disease from plasma

NCT ID: NCT02588430 Withdrawn - Clinical trials for Retinitis Pigmentosa

PMCF Study for Partial Vision Restoration Using the Subretinal Implant RETINA IMPLANT Alpha AMS

Start date: March 2019
Phase:
Study type: Observational [Patient Registry]

This study is a post-market clinical follow-up (PMCF) study to monitor the safety, lifetime and efficacy of patients using the CE-certified RETINA IMPLANT Alpha AMS.

NCT ID: NCT02583945 Withdrawn - Acute Kidney Injury Clinical Trials

Prevention of Postoperative Acute Kidney Injury

PrevenAKI
Start date: October 2015
Phase: N/A
Study type: Interventional

Postoperative acute kidney injury (AKI) refers to increased mortality and morbidity in patients after non-cardiac surgery. The Kidney Disease Improving Global Outcomes (KDIGO)-guidelines recommend a bundle of procedures to prevent the occurrence of AKI: A protocol for the improvement of the hemodynamic situation and a standardized proceeding in hemodynamic monitoring, consequent avoidance of nephrotoxic substances, regular measurement of creatinine and urine output, as well as normoglycemia. The primary goal is to determine if the consequent application of the KDIGO-bundle leads to a prevention of the occurrence of AKI in patients at risk after non-cardiac surgery.